Birner A, Hültner L, Mergenthaler H G, van Snick J, Dörmer P
GSF-Institute for Experimental Hematology, Munich, FRG.
Exp Hematol. 1992 Jun;20(5):541-5.
Murine interleukin 9 (mIL-9) is a novel T-cell-derived lymphokine previously described as a T-cell growth factor (P40/TCGFIII) and as a mast cell growth-enhancing activity (MEA). In the present study we examined the potency of recombinant (r)mIL-9 to exhibit hemopoietic growth factor activity in the human system. In semisolid cultures of normal human bone marrow-derived mononuclear cells, rmIL-9 alone at a concentration range from 25 to 200 U/ml did not reveal any colony-stimulating activity on human granulocyte-macrophage colony-forming cells (GM-CFC), erythroid colony-forming units (CFU-E), and erythroid burst-forming units (BFU-E). Furthermore, we did not observe synergistic effects of rmIL-9 on the number, size, and morphological composition of human granulocyte-macrophage colonies in cultures stimulated with giant cell tumor-conditioned medium. However, a synergistic effect of rmIL-9 in the human erythropoietic culture system was clearly demonstrated in the presence of recombinant human erythropoietin (rhEpo). Recombinant murine IL-9 at a concentration of 200 U/ml enhanced the number of BFU-E-derived day-14 colonies about 3.6-fold as compared to control cultures stimulated with Epo alone. The formation of CFU-E-derived day-7 colonies was not significantly altered under the same conditions. Our results demonstrate that in the presence of rhEpo, rmIL-9 is synergistically active in human bone marrow cultures as an erythroid burst-promoting factor. The development of granulocyte-macrophage colonies obviously is not affected. This finding strongly suggests that mIL-9 can mediate signals via human IL-9 receptors and further extends the range of biological activities hitherto ascribed to mIL-9.
小鼠白细胞介素9（mIL-9）是一种新的T细胞衍生的淋巴因子，以前被描述为T细胞生长因子（P40/TCGFIII）和肥大细胞生长增强活性因子（MEA）。在本研究中，我们检测了重组（r）mIL-9在人体系统中表现造血生长因子活性的能力。在正常人骨髓来源的单个核细胞的半固体培养中，单独使用浓度范围为25至200 U/ml的rmIL-9对人粒细胞-巨噬细胞集落形成细胞（GM-CFC）、红系集落形成单位（CFU-E）和红系爆式集落形成单位（BFU-E）未显示出任何集落刺激活性。此外，在用巨细胞瘤条件培养基刺激的培养物中，我们未观察到rmIL-9对人粒细胞-巨噬细胞集落的数量、大小和形态组成的协同作用。然而，在重组人促红细胞生成素（rhEpo）存在的情况下，rmIL-9在人红细胞生成培养系统中的协同作用得到了明确证明。与单独用Epo刺激的对照培养物相比，浓度为200 U/ml的重组小鼠IL-9使BFU-E来源的第14天集落数量增加了约3.6倍。在相同条件下，CFU-E来源的第7天集落的形成没有明显改变。我们的结果表明，在rhEpo存在的情况下，rmIL-9作为一种红系爆式促进因子在人骨髓培养中具有协同活性。粒细胞-巨噬细胞集落的发育显然不受影响。这一发现强烈表明，mIL-9可以通过人IL-9受体介导信号，并进一步扩展了迄今为止归因于mIL-9的生物活性范围。
